{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:06:33Z","timestamp":1751429193396,"version":"3.41.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Natural Science Foundation of China","award":["No.23ZR1410200","No.23ZR1410000"],"award-info":[{"award-number":["No.23ZR1410200","No.23ZR1410000"]}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["No.YWP2023-001"],"award-info":[{"award-number":["No.YWP2023-001"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00428-024-03884-8","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:56:21Z","timestamp":1748260581000},"page":"1153-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients"],"prefix":"10.1007","volume":"486","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieakesu","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-2305","authenticated-orcid":false,"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"3","key":"3884_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"10110","key":"3884_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","volume":"390","author":"J Lagergren","year":"2017","unstructured":"Lagergren J, Smyth E, Cunningham D, Lagergren P (2017) Oesophageal cancer. Lancet 390(10110):2383\u20132396. https:\/\/doi.org\/10.1016\/S0140-6736(17)31462-9","journal-title":"Lancet"},{"issue":"1","key":"3884_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/cancers13010141","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang J, Koulaouzidis A, Marlicz W et al (2021) Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries. Cancers (Basel) 13(1):141. https:\/\/doi.org\/10.3390\/cancers13010141","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3884_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/2050640617751254","volume":"6","author":"SH Xie","year":"2018","unstructured":"Xie SH, Lagergren J (2018) Social group disparities in the incidence and prognosis of oesophageal cancer. United Eur Gastroenterol J 6(3):343\u2013348. https:\/\/doi.org\/10.1177\/2050640617751254","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"3884_CR5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","volume":"13","author":"DJ Uhlenhopp","year":"2020","unstructured":"Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13(6):1010\u20131021. https:\/\/doi.org\/10.1007\/s12328-020-01237-x","journal-title":"Clin J Gastroenterol"},{"issue":"2","key":"3884_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ijc.34232","volume":"152","author":"L An","year":"2023","unstructured":"An L, Zheng R, Zeng H et al (2023) The survival of esophageal cancer by subtype in China with comparison to the United States. Int J Cancer 152(2):151\u2013161. https:\/\/doi.org\/10.1002\/ijc.34232","journal-title":"Int J Cancer"},{"issue":"3","key":"3884_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64(3):381\u2013387. https:\/\/doi.org\/10.1136\/gutjnl-2014-308124","journal-title":"Gut"},{"issue":"2","key":"3884_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","volume":"154","author":"CC Abnet","year":"2018","unstructured":"Abnet CC, Arnold M, Wei WQ (2018) Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154(2):360\u2013373. https:\/\/doi.org\/10.1053\/j.gastro.2017.08.023","journal-title":"Gastroenterology"},{"issue":"5","key":"3884_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386(5):449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"issue":"1","key":"3884_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","volume":"5","author":"YM Yang","year":"2020","unstructured":"Yang YM, Hong P, Xu WW, He QY, Li B (2020) Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 5(1):229. https:\/\/doi.org\/10.1038\/s41392-020-00323-3","journal-title":"Signal Transduct Target Ther"},{"key":"3884_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","volume":"69","author":"SR Hubbard","year":"2000","unstructured":"Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373\u2013398. https:\/\/doi.org\/10.1146\/annurev.biochem.69.1.373","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"3884_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jb\/mvq121","volume":"149","author":"N Itoh","year":"2011","unstructured":"Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149(2):121\u2013130. https:\/\/doi.org\/10.1093\/jb\/mvq121","journal-title":"J Biochem"},{"issue":"4","key":"3884_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","volume":"26","author":"LH Gallo","year":"2015","unstructured":"Gallo LH, Nelson KN, Meyer AN, Donoghue DJ (2015) Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev 26(4):425\u2013449. https:\/\/doi.org\/10.1016\/j.cytogfr.2015.03.003","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"3884_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H (2014) FGF receptors: cancer biology and therapeutics. Med Res Rev 34(2):280\u2013300. https:\/\/doi.org\/10.1002\/med.21288","journal-title":"Med Res Rev"},{"issue":"5","key":"3884_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17(5):318\u2013332. https:\/\/doi.org\/10.1038\/nrc.2017.8","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3884_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155220983425","volume":"27","author":"A Weaver","year":"2021","unstructured":"Weaver A, Bossaer JB (2021) Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. J Oncol Pharm Pract 27(3):702\u2013710. https:\/\/doi.org\/10.1177\/1078155220983425","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"3884_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","volume":"81","author":"C Kang","year":"2021","unstructured":"Kang C (2021) Infigratinib: first approval. Drugs 81(11):1355\u20131360. https:\/\/doi.org\/10.1007\/s40265-021-01567-1","journal-title":"Drugs"},{"issue":"18","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY (2022) Futibatinib: first approval. Drugs 82(18):1737\u20131743. https:\/\/doi.org\/10.1007\/s40265-022-01806-z","journal-title":"Drugs"},{"issue":"1","key":"3884_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R (2016) The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 22(1):259\u2013267. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3212","journal-title":"Clin Cancer Res"},{"issue":"22","key":"3884_CR20","doi-asserted-by":"publisher","first-page":"6695","DOI":"10.7150\/jca.49269","volume":"11","author":"W Zuo","year":"2020","unstructured":"Zuo W, He Y, Li W et al (2020) Landscape of FGF\/FGFR alterations in 12,372 chinese cancer patients. J Cancer 11(22):6695\u20136699. https:\/\/doi.org\/10.7150\/jca.49269","journal-title":"J Cancer"},{"issue":"20","key":"3884_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.21037\/atm-20-5118","volume":"8","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li G, Zhu W et al (2020) A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients. Ann Transl Med 8(20):1290. https:\/\/doi.org\/10.21037\/atm-20-5118","journal-title":"Ann Transl Med"},{"issue":"44","key":"3884_CR22","doi-asserted-by":"publisher","first-page":"9803","DOI":"10.3748\/wjg.v22.i44.9803","volume":"22","author":"D Kwon","year":"2016","unstructured":"Kwon D, Yun JY, Keam B, Kim YT, Jeon YK (2016) Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma. World J Gastroenterol 22(44):9803\u20139812. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9803","journal-title":"World J Gastroenterol"},{"issue":"43","key":"3884_CR23","doi-asserted-by":"publisher","first-page":"74539","DOI":"10.18632\/oncotarget.20215","volume":"8","author":"Q Song","year":"2017","unstructured":"Song Q, Liu Y, Jiang D et al (2017) High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients. Oncotarget 8(43):74539\u201374553. https:\/\/doi.org\/10.18632\/oncotarget.20215","journal-title":"Oncotarget"},{"issue":"4","key":"3884_CR24","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.18632\/oncotarget.2944","volume":"6","author":"HS Kim","year":"2015","unstructured":"Kim HS, Lee SE, Bae YS et al (2015) Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 6(4):2562\u20132572. https:\/\/doi.org\/10.18632\/oncotarget.2944","journal-title":"Oncotarget"},{"issue":"6","key":"3884_CR25","doi-asserted-by":"publisher","first-page":"101042831770742","DOI":"10.1177\/1010428317707424","volume":"39","author":"G Liu","year":"2017","unstructured":"Liu G, Xiong D, Xiao R, Huang Z (2017) Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis. Tumour Biol 39(6):1010428317707424. https:\/\/doi.org\/10.1177\/1010428317707424","journal-title":"Tumour Biol"},{"issue":"15","key":"3884_CR26","doi-asserted-by":"publisher","first-page":"19748","DOI":"10.18632\/oncotarget.7782","volume":"7","author":"R Tokunaga","year":"2016","unstructured":"Tokunaga R, Imamura Y, Nakamura K et al (2016) Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget 7(15):19748\u201319761. https:\/\/doi.org\/10.18632\/oncotarget.7782","journal-title":"Oncotarget"},{"key":"3884_CR27","doi-asserted-by":"publisher","first-page":"2872479","DOI":"10.1155\/2020\/2872479","volume":"2020","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhou Y, Li C et al (2020) The expression and prognostic value of FGF2, FGFR3, and FGFBP1 in esophageal squamous cell carcinoma. Anal Cell Pathol (Amst) 2020:2872479. https:\/\/doi.org\/10.1155\/2020\/2872479","journal-title":"Anal Cell Pathol (Amst)"},{"key":"3884_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1746-1596-8-9","volume":"8","author":"Y Shi","year":"2013","unstructured":"Shi Y, He D, Hou Y et al (2013) An alternative high output tissue microarray technique. Diagn Pathol 8:9. https:\/\/doi.org\/10.1186\/1746-1596-8-9","journal-title":"Diagn Pathol"},{"issue":"8","key":"3884_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/labinvest.2014.77","volume":"94","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jiang D, Li X et al (2014) Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest 94(8):917\u2013926. https:\/\/doi.org\/10.1038\/labinvest.2014.77","journal-title":"Lab Invest"},{"issue":"11","key":"3884_CR30","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","volume":"25","author":"HU Schildhaus","year":"2012","unstructured":"Schildhaus HU, Heukamp LC, Merkelbach-Bruse S et al (2012) Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 25(11):1473\u20131480. https:\/\/doi.org\/10.1038\/modpathol.2012.102","journal-title":"Mod Pathol"},{"issue":"3","key":"3884_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s10549-011-1883-6","volume":"133","author":"JP Cerliani","year":"2012","unstructured":"Cerliani JP, Vanzulli SI, Pi\u00f1ero CP et al (2012) Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 133(3):997\u20131008. https:\/\/doi.org\/10.1007\/s10549-011-1883-6","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"3884_CR32","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ijc.34301","volume":"152","author":"H Zhu","year":"2023","unstructured":"Zhu H, Ma X, Ye T et al (2023) Esophageal cancer in China: Practice and research in the new era. Int J Cancer 152(9):1741\u20131751. https:\/\/doi.org\/10.1002\/ijc.34301","journal-title":"Int J Cancer"},{"issue":"5","key":"3884_CR33","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/cam4.3775","volume":"10","author":"S Li","year":"2021","unstructured":"Li S, Chen H, Man J et al (2021) Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years. Cancer Med 10(5):1889\u20131899. https:\/\/doi.org\/10.1002\/cam4.3775","journal-title":"Cancer Med"},{"issue":"13","key":"3884_CR34","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.7150\/jca.19601","volume":"8","author":"Q Song","year":"2017","unstructured":"Song Q, Jiang D, Wang H et al (2017) Chromosomal and genomic variations in esophageal squamous cell carcinoma: a review of technologies, applications, and prospections. J Cancer 8(13):2492\u20132500. https:\/\/doi.org\/10.7150\/jca.19601","journal-title":"J Cancer"},{"issue":"5","key":"3884_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/his.12473","volume":"66","author":"A Fischbach","year":"2015","unstructured":"Fischbach A, Rogler A, Erber R et al (2015) Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology 66(5):639\u2013649. https:\/\/doi.org\/10.1111\/his.12473","journal-title":"Histopathology"},{"issue":"4","key":"3884_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cjp2.51","volume":"2","author":"WS Theelen","year":"2016","unstructured":"Theelen WS, Mittempergher L, Willems SM et al (2016) FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. J Pathol Clin Res 2(4):223\u2013233. https:\/\/doi.org\/10.1002\/cjp2.51","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"3884_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jop.12394","volume":"45","author":"T Ach","year":"2016","unstructured":"Ach T, Schwarz-Furlan S, Ach S et al (2016) Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. J Oral Pathol Med 45(7):500\u2013509. https:\/\/doi.org\/10.1111\/jop.12394","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"3884_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cam4.595","volume":"5","author":"K Koole","year":"2016","unstructured":"Koole K, van Kempen PM, Swartz JE et al (2016) Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med 5(2):275\u2013284. https:\/\/doi.org\/10.1002\/cam4.595","journal-title":"Cancer Med"},{"issue":"2","key":"3884_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza C, Guidi L, Battaiotto E et al (2024) Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer 10(2):113\u2013123. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.001","journal-title":"Trends Cancer"},{"issue":"8","key":"3884_CR40","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1007\/s00432-022-04460-w","volume":"149","author":"J Albin","year":"2023","unstructured":"Albin J, Fahrig L, Siemanowski J et al (2023) FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 149(8):5289\u20135300. https:\/\/doi.org\/10.1007\/s00432-022-04460-w","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3884_CR41","doi-asserted-by":"publisher","first-page":"e0143207","DOI":"10.1371\/journal.pone.0143207","volume":"10","author":"P Ye","year":"2015","unstructured":"Ye P, Zhang M, Fan S et al (2015) Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS one 10(11):e0143207. https:\/\/doi.org\/10.1371\/journal.pone.0143207","journal-title":"PLoS one"},{"issue":"4","key":"3884_CR42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1073\/pnas.88.4.1095","volume":"88","author":"K Keegan","year":"1991","unstructured":"Keegan K, Johnson DE, Williams LT, Hayman MJ (1991) Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A 88(4):1095\u20131099. https:\/\/doi.org\/10.1073\/pnas.88.4.1095","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3884_CR43","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0888-7543(91)90041-c","volume":"11","author":"LM Thompson","year":"1991","unstructured":"Thompson LM, Plummer S, Schalling M et al (1991) A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics 11(4):1133\u20131142. https:\/\/doi.org\/10.1016\/0888-7543(91)90041-c","journal-title":"Genomics"},{"issue":"2","key":"3884_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1042\/BJ20101603","volume":"437","author":"J Wesche","year":"2011","unstructured":"Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437(2):199\u2013213. https:\/\/doi.org\/10.1042\/BJ20101603","journal-title":"Biochem J"},{"issue":"1","key":"3884_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1369\/0022155415616161","volume":"64","author":"N Ueno","year":"2016","unstructured":"Ueno N, Shimizu A, Kanai M et al (2016) Enhanced expression of fibroblast growth factor receptor 3 IIIc promotes human esophageal carcinoma cell proliferation. J Histochem Cytochem 64(1):7\u201317. https:\/\/doi.org\/10.1369\/0022155415616161","journal-title":"J Histochem Cytochem"},{"issue":"2 Pt 1","key":"3884_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","volume":"11","author":"JJ G\u00f3mez-Rom\u00e1n","year":"2005","unstructured":"G\u00f3mez-Rom\u00e1n JJ, Saenz P, Molina M et al (2005) Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 11(2 Pt 1):459\u2013465","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3884_CR47","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/ijc.26304","volume":"130","author":"DC Tomlinson","year":"2012","unstructured":"Tomlinson DC, Knowles MA, Speirs V (2012) Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 130(12):2857\u20132866. https:\/\/doi.org\/10.1002\/ijc.26304","journal-title":"Int J Cancer"},{"issue":"7","key":"3884_CR48","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bjc.6605596","volume":"102","author":"G Sonvilla","year":"2010","unstructured":"Sonvilla G, Allerstorfer S, Heinzle C et al (2010) Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer 102(7):1145\u20131156. https:\/\/doi.org\/10.1038\/sj.bjc.6605596","journal-title":"Br J Cancer"},{"issue":"11","key":"3884_CR49","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","volume":"8","author":"EM Haugsten","year":"2010","unstructured":"Haugsten EM, Wiedlocha A, Olsnes S, Wesche J (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8(11):1439\u20131452. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0168","journal-title":"Mol Cancer Res"},{"issue":"38","key":"3884_CR50","doi-asserted-by":"publisher","first-page":"61166","DOI":"10.18632\/oncotarget.11278","volume":"7","author":"X Zhong","year":"2016","unstructured":"Zhong X, Xie G, Zhang Z et al (2016) MiR-4653\u20133p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget 7(38):61166\u201361182. https:\/\/doi.org\/10.18632\/oncotarget.11278","journal-title":"Oncotarget"},{"issue":"1","key":"3884_CR51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2005-01-0033","volume":"106","author":"H Chang","year":"2005","unstructured":"Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106(1):353\u2013355. https:\/\/doi.org\/10.1182\/blood-2005-01-0033","journal-title":"Blood"},{"issue":"4","key":"3884_CR52","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/cam4.262","volume":"3","author":"EA Guancial","year":"2014","unstructured":"Guancial EA, Werner L, Bellmunt J et al (2014) FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 3(4):835\u2013844. https:\/\/doi.org\/10.1002\/cam4.262","journal-title":"Cancer Med"},{"issue":"1","key":"3884_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.humpath.2007.05.027","volume":"39","author":"M Woenckhaus","year":"2008","unstructured":"Woenckhaus M, Merk J, Stoehr R et al (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39(1):126\u2013136. https:\/\/doi.org\/10.1016\/j.humpath.2007.05.027","journal-title":"Hum Pathol"},{"key":"3884_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euros.2020.08.008","volume":"21","author":"S Khalid","year":"2020","unstructured":"Khalid S, Basulaiman BM, Emack J et al (2020) Fibroblast growth factor receptor 3 mutation as a prognostic indicator in patients with urothelial carcinoma: a systematic review and meta-analysis. Eur Urol Open Sci 21:61\u201368. https:\/\/doi.org\/10.1016\/j.euros.2020.08.008","journal-title":"Eur Urol Open Sci"},{"key":"3884_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/RRU.S37355","volume":"4","author":"SR Lyle","year":"2012","unstructured":"Lyle SR, Hsieh CC, Fernandez CA, Shuber AP (2012) Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis. Res Rep Urol 4:65\u201369. https:\/\/doi.org\/10.2147\/RRU.S37355","journal-title":"Res Rep Urol"},{"issue":"40","key":"3884_CR56","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","volume":"26","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson DC, Hurst CD, Knowles MA (2007) Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26(40):5889\u20135899. https:\/\/doi.org\/10.1038\/sj.onc.1210399","journal-title":"Oncogene"},{"issue":"5","key":"3884_CR57","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI38017","volume":"119","author":"J Qing","year":"2009","unstructured":"Qing J, Du X, Chen Y et al (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 119(5):1216\u20131229. https:\/\/doi.org\/10.1172\/JCI38017","journal-title":"J Clin Invest"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03884-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:57:51Z","timestamp":1751349471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03884-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03884-8","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Human Research Ethics Committee of Zhongshan Hospital, Fudan University. In accordance with the Declaration of Helsinki, informed consent was obtained from each patient for the collection and use of tissue samples and clinical data (Ethics number: B2021-178R).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}